US FDA Issues Study May Proceed Letter For Pidnarulex
14 Oct 2024 //
PR NEWSWIRE
Senhwa Submits IND For Pidnarulex Study In Advanced Solid Tumors To US FDA
17 Sep 2024 //
PR NEWSWIRE
Senhwa Presents Pidnarulex Clinical Data At ESMO 2024
08 Sep 2024 //
PR NEWSWIRE
Senhwa Announces Successful Awardee of Anticancer Pipeline in NExT Program
01 Dec 2022 //
PRNEWSWIRE
Senhwa`s Pidnarulex Receives US FDA FTD for Solid Tumors with BRCA1/2, PALB2
25 Jan 2022 //
PRNEWSWIRE
Senhwa initiates dosing in PIb expansion study of Pidnarulex in solid tumors
13 Sep 2021 //
PHARMABIZ